Entrada Therapeutics/$TRDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Entrada Therapeutics
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Ticker
$TRDA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
183
ISIN
US29384C1080
Website
TRDA Metrics
BasicAdvanced
$237M
11.08
$0.61
0.03
-
Price and volume
Market cap
$237M
Beta
0.03
52-week high
$21.19
52-week low
$6.70
Average daily volume
145K
Financial strength
Current ratio
21.876
Quick ratio
21
Long term debt to equity
12.1
Total debt to equity
13.66
Profitability
EBITDA (TTM)
7.893
Gross margin (TTM)
25.23%
Net profit margin (TTM)
14.39%
Operating margin (TTM)
2.39%
Effective tax rate (TTM)
-4.08%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
0.51%
Return on equity (TTM)
7.22%
Valuation
Price to earnings (TTM)
11.076
Price to revenue (TTM)
1.53
Price to book
0.57
Price to tangible book (TTM)
0.57
Price to free cash flow (TTM)
-4.541
Free cash flow yield (TTM)
-22.02%
Free cash flow per share (TTM)
-147.98%
Growth
Revenue change (TTM)
5.74%
Earnings per share change (TTM)
-13.89%
3-year earnings per share growth (CAGR)
-49.40%
What the Analysts think about TRDA
Analyst ratings (Buy, Hold, Sell) for Entrada Therapeutics stock.
TRDA Financial Performance
Revenues and expenses
TRDA Earnings Performance
Company profitability
TRDA News
AllArticlesVideos
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Entrada Therapeutics stock?
Entrada Therapeutics (TRDA) has a market cap of $237M as of July 01, 2025.
What is the P/E ratio for Entrada Therapeutics stock?
The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 11.08 as of July 01, 2025.
Does Entrada Therapeutics stock pay dividends?
No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Entrada Therapeutics dividend payment date?
Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Entrada Therapeutics?
Entrada Therapeutics (TRDA) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.